Oppenheimer Comments on Alpine Immune Sciences, Inc.’s Q1 2023 Earnings (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) – Stock analysts at Oppenheimer issued their Q1 2023 earnings estimates for shares of Alpine Immune Sciences in a research note issued to investors on Wednesday, June 1st. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings per share of ($0.50) for the quarter. Oppenheimer also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.50) EPS, Q3 2023 earnings at ($0.52) EPS and Q4 2023 earnings at ($0.54) EPS.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last released its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative return on equity of 46.87% and a negative net margin of 139.41%.

A number of other equities research analysts have also recently issued reports on ALPN. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Alpine Immune Sciences in a research report on Friday, May 13th. Zacks Investment Research cut shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Alpine Immune Sciences in a research report on Tuesday, May 17th.

ALPN stock opened at $9.04 on Friday. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $8.63 and a two-hundred day moving average price of $9.60. Alpine Immune Sciences has a one year low of $6.00 and a one year high of $14.40.

Several institutional investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc boosted its position in shares of Alpine Immune Sciences by 50.9% in the first quarter. Ensign Peak Advisors Inc now owns 110,017 shares of the biotechnology company’s stock valued at $987,000 after acquiring an additional 37,087 shares during the period. Goldman Sachs Group Inc. raised its stake in Alpine Immune Sciences by 70.8% in the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 9,471 shares in the last quarter. State Street Corp raised its stake in Alpine Immune Sciences by 7.1% in the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock valued at $1,979,000 after purchasing an additional 14,609 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new position in Alpine Immune Sciences in the first quarter valued at about $3,016,000. Finally, Frazier Life Sciences Management L.P. acquired a new position in Alpine Immune Sciences in the first quarter valued at about $37,546,000. 77.00% of the stock is owned by institutional investors.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Articles

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.